GlassScriptPhysician profile
Saira Farid
NPI 1659876894
$751.89
in general payments reported to CMS, 2019-2025
23 companies · $526 in 2025
The $526 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $226 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $752.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $751.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $83.87 | 2024-2025 | Erleada, Balversa, Carvykti |
| Daiichi Sankyo INC. | $83.24 | 2024-2025 | Enhertu |
| Merck Sharp & Dohme LLC | $57.34 | 2024-2025 | Keytruda, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $51.72 | 2024-2025 | Opdualag, Opdivo |
| Novartis Pharmaceuticals Corporation | $49.58 | 2024-2025 | |
| Lilly USA, LLC | $47.08 | 2025 | Verzenio, Jaypirca |
| Astrazeneca Pharmaceuticals LP | $40.99 | 2025 | Imfinzi, Enhertu |
| Aveo Pharmaceuticals, INC. | $31.50 | 2025 | |
| Astellas Pharma US INC | $25.96 | 2025 | Vyloy |
| Genentech USA, INC. | $22.91 | 2025 | Venclexta |
| Jazz Pharmaceuticals INC. | $22.82 | 2024 | |
| Kyowa Kirin, INC. | $22.10 | 2024 | Poteligeo |
| Beigene USA, INC. | $21.76 | 2024 | Brukinsa |
| Exelixis INC. | $21.10 | 2025 | Cabometyx |
| Stemline Therapeutics INC. | $20.99 | 2025 | Orserdu |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Caris Mpi, INC. | $20.53 | 2025 | Mi Cancer Seek |
| Pfizer INC. | $20.40 | 2025 | |
| Glaxosmithkline, LLC. | $19.82 | 2024 | Ojjaara |
| Celgene Corporation | $19.00 | 2025 | Opdivo |
| Genzyme Corporation | $18.53 | 2025 | |
| Pharmacosmos Therapeutics INC. | $17.00 | 2025 | Monoferric |
| Puma Biotechnology, INC. | $16.86 | 2025 | |
| Array Biopharma INC | $16.79 | 2024 | Braftovi, Lorbrena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saira Farid listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.